慢性便秘和其他功能性肠道疾病的新视角。

Brooks D Cash, Eugene Chang, Nicholas J Talley, Arnold Wald
{"title":"慢性便秘和其他功能性肠道疾病的新视角。","authors":"Brooks D Cash,&nbsp;Eugene Chang,&nbsp;Nicholas J Talley,&nbsp;Arnold Wald","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Functional bowel disorders (FBDs) such as chronic constipation and irritable bowel syndrome-constipation predominant (IBS-C) often share symptoms, but thanks to advances such as the Rome III criteria, diagnosis of these conditions in the absence of alarm features can be relatively straightforward. Empiric treatment is recommended for most patients, with diagnostic testing reserved for those with alarm symptoms. Most current therapies for constipation are indicated for patients with occasional symptoms, with only lubiprostone and tegaserod (restricted) indicated for chronic constipation. Therapies for IBS-C also are limited. However, ongoing research provides promise for improved outcomes in patients with FBDs.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"7 3","pages":"116-33"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fresh perspectives in chronic constipation and other functional bowel disorders.\",\"authors\":\"Brooks D Cash,&nbsp;Eugene Chang,&nbsp;Nicholas J Talley,&nbsp;Arnold Wald\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Functional bowel disorders (FBDs) such as chronic constipation and irritable bowel syndrome-constipation predominant (IBS-C) often share symptoms, but thanks to advances such as the Rome III criteria, diagnosis of these conditions in the absence of alarm features can be relatively straightforward. Empiric treatment is recommended for most patients, with diagnostic testing reserved for those with alarm symptoms. Most current therapies for constipation are indicated for patients with occasional symptoms, with only lubiprostone and tegaserod (restricted) indicated for chronic constipation. Therapies for IBS-C also are limited. However, ongoing research provides promise for improved outcomes in patients with FBDs.</p>\",\"PeriodicalId\":21173,\"journal\":{\"name\":\"Reviews in gastroenterological disorders\",\"volume\":\"7 3\",\"pages\":\"116-33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in gastroenterological disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in gastroenterological disorders","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

功能性肠病(fbd),如慢性便秘和肠易激综合征-便秘为主(IBS-C)通常有共同的症状,但由于罗马III标准等进步,在没有警报特征的情况下诊断这些疾病相对简单。大多数患者建议经验性治疗,诊断测试保留给那些有警报症状的患者。目前大多数治疗便秘的方法适用于偶尔出现症状的患者,只有卢比前列酮和泰加塞罗德(限制性)适用于慢性便秘。IBS-C的治疗方法也很有限。然而,正在进行的研究为改善fbd患者的预后提供了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Fresh perspectives in chronic constipation and other functional bowel disorders.

Functional bowel disorders (FBDs) such as chronic constipation and irritable bowel syndrome-constipation predominant (IBS-C) often share symptoms, but thanks to advances such as the Rome III criteria, diagnosis of these conditions in the absence of alarm features can be relatively straightforward. Empiric treatment is recommended for most patients, with diagnostic testing reserved for those with alarm symptoms. Most current therapies for constipation are indicated for patients with occasional symptoms, with only lubiprostone and tegaserod (restricted) indicated for chronic constipation. Therapies for IBS-C also are limited. However, ongoing research provides promise for improved outcomes in patients with FBDs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信